Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology leader developing innovative therapies for rare diseases and infectious conditions through targeted enzyme inhibition. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on BCRX's pipeline progress, including updates on hereditary angioedema treatments and antiviral therapies. Our curated collection features earnings announcements, research breakthroughs, and partnership disclosures – all essential for tracking this biopharma innovator.
Key updates include FDA decisions, clinical trial results, and scientific publications. Bookmark this page for streamlined access to verified BioCryst news, eliminating the need to monitor multiple sources. Check regularly for developments impacting the company's position in enzyme inhibitor therapeutics and rare disease treatment markets.
BioCryst (Nasdaq: BCRX) reported APeX-P second interim data and psychosocial findings at ACAAI on Nov 6, 2025. An oral granule formulation of ORLADEYO (berotralstat) for ages 2 to <12 is under FDA review with a target action date of Dec 12, 2025. In 29 pediatric participants (mean exposure 63.9 weeks), ORLADEYO produced early and sustained reductions in attacks: 65.5% attack-free at month 1, 70.4% attack-free at month 12, and a median monthly attack rate of 0 for 11 of 12 months. Continuation was high (93.1% completed ≥48 weeks). Safety findings reported no new signals; most common TEAE was nasopharyngitis. Separate posters documented early-onset HAE (median diagnosis age 2.0) and frequent, stressful ED/hospital visits for children and caregivers.
BioCryst (Nasdaq: BCRX) granted inducement restricted stock units covering an aggregate of 30,700 shares to three newly hired employees, effective November 3, 2025.
The awards were approved by the compensation committee as inducements under Nasdaq Listing Rule 5635(c)(4) and are governed by the company’s Inducement Equity Incentive Plan and individual RSU agreements. The RSUs vest in four equal annual installments beginning on the one‑year anniversary of the grant, each installment subject to the employee’s continued service.
BioCryst (Nasdaq:BCRX) will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 12:00 p.m. ET.
The event will be available via a live audio webcast with a replay. Investors can access the live audio and replay in the Investors & Media section at www.biocryst.com.
BioCryst (Nasdaq:BCRX) reported strong Q3 2025 results driven by ORLADEYO: Q3 ORLADEYO net revenue $159.1M (+37% y-o-y), operating income $29.6M (+285% y-o-y) and non-GAAP operating income $51.7M (+107% y-o-y). The company raised FY2025 ORLADEYO revenue guidance to $590–$600M and lowered FY2025 non-GAAP operating expense guidance to $430–$440M. BioCryst completed the sale of its European ORLADEYO business and used proceeds to retire the Pharmakon term loan. A definitive agreement to acquire Astria Therapeutics was signed; the transaction is expected to close in Q1 2026. Pro forma cash at Sept 30, 2025 was $294M.
BioCryst (Nasdaq: BCRX) will present four abstracts at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting in Orlando, Nov 6–10, 2025.
Planned presentations include a second interim analysis from the APeX-P trial evaluating long-term prophylaxis with once-daily oral granule ORLADEYO (berotralstat) in pediatric hereditary angioedema (HAE) patients aged 2 to <12 years, plus three ePosters on psychosocial burden, caregiver impact, and emergency department experiences for young HAE patients.
Individual ePoster sessions are scheduled Nov 7–9, 2025, and all ePosters will be available online on Nov 6, 2025 at 8:00 a.m. ET to registered attendees.
BioCryst (Nasdaq: BCRX) will report third quarter 2025 financial results on Monday, November 3, 2025. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
Dial-in numbers are 1-844-481-2942 (U.S.) and 1-412-317-1866 (international). A live webcast and replay will be available in the investors section of the company website at www.biocryst.com.
BioCryst (Nasdaq: BCRX) agreed to acquire Astria Therapeutics (Nasdaq: ATXS) for an implied value of $13.00 per ATXS share and about $700 million enterprise value. The deal combines BioCryst’s oral HAE franchise with Astria’s injectable Phase 3 candidate navenibart, which has pivotal ALPHA-ORBIT topline data expected in early 2027. BioCryst expects to remain non-GAAP profitable and cash flow positive after closing and to be accretive to operating profit in the first full year after navenibart launch. Closing is expected in Q1 2026, subject to approvals; Astria stockholders would own ~15% of the combined company.
BioCryst (Nasdaq: BCRX) announced on October 3, 2025 that its compensation committee granted inducement equity awards to eight newly hired employees.
The package includes 115,000 stock options and 91,450 restricted stock units (RSUs), granted effective October 1, 2025 under Nasdaq Listing Rule 5635(c)(4). Options carry an exercise price of $7.37 (closing price on the grant date), vest in four equal annual installments beginning one year after grant, and have a 10-year term. Awards are subject to the company’s Inducement Equity Incentive Plan and applicable award agreements.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million upfront, with potential additional milestones of up to $14 million. The transaction represents a multiple of 5.4x last twelve months sales through June 2025.
Despite the European business divestiture, BioCryst maintains its 2025 revenue guidance of $580-600 million. The company plans to use the proceeds to retire its $199 million Pharmakon term loan. The deal allows BioCryst to focus on its core U.S. market while Neopharmed Gentili will lead European commercialization, retaining the existing European commercial team.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has granted equity-based compensation to nine newly-hired employees as employment inducements. The compensation package includes:
- Stock options to purchase 36,700 shares at $8.29 per share (equal to closing price on grant date)
- Restricted stock units (RSUs) covering 71,400 shares of common stock
Both options and RSUs were granted on September 2, 2025, and will vest in four equal annual installments. The options have a 10-year term and were granted under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
